Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016) [0.03%]
次黄嘌呤核苷酸脱氢酶抑制剂的专利和文献综述（2002-2016）
Gregory D Cuny,Chalada Suebsuwong,Soumya S Ray
Gregory D Cuny
Inosine-5'-monophosphate dehydrogenase (IMPDH) is an enzyme involved in the de novo biosynthesis of guanine nucleotides. To date human IMPDH inhibitors have been approved for prevention of organ transplant rejection and as anti-viral agents...
mGlu5 negative allosteric modulators: a patent review (2013 - 2016) [0.03%]
代谢型谷氨酸受体5负向变构调节剂的专利回顾(2013-2016)
Kyle A Emmitte
Kyle A Emmitte
The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clini...
Recent advances of pyrrolopyridines derivatives: a patent and literature review [0.03%]
吡咯并吡啶类衍生物的研究进展：专利与文献综述
Mohammed I El-Gamal,Hanan S Anbar
Mohammed I El-Gamal
Several pyrrolopyridines or azaindoles have been reported in the literature as biologically-active molecules. Most of them are anticancer agents, and few possess other therapeutic effects. Areas covered: The most recent biologically-active ...
Corrigendum [0.03%]
勘误表
Published Erratum
Expert opinion on therapeutic patents. 2017 Feb;27(2):227. DOI:10.1080/13543776.2017.1279813 2017
Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1) [0.03%]
茋类生物碱化合物、组合物及其用法：关于WO2015042239(A1)的专利评估
Takehiko Yoshimitsu,Han W Tun
Takehiko Yoshimitsu
Agelastatins are a family of tetracyclic alkaloids isolated from marine sponges. The patent examined in this publication covers the chemical synthesis of agelastatins A to F and eight analogues and their therapeutic use against hematologic ...
Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016) [0.03%]
σ受体激动剂是抗癌药物研发的有效途径吗？1996-2016年专利分析报告摘要
Simona Collina,Emanuele Bignardi,Marta Rui et al.
Simona Collina et al.
Although several molecular targets against cancer have been identified, there is a continuous need for new therapeutic strategies. Sigma Receptors (SRs) overexpression has been recently associated with different cancer conditions. Therefore...
Olivier Defert,Sandro Boland
Olivier Defert
The Rho-kinases (ROCK), ROCK1 and ROCK2, are potent, widespread biochemical modulators which have been extensively studied. Due to the involvement of ROCKs in multiple biological processes, ROCK inhibitors have pleiotropic actions and may b...
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives [0.03%]
组蛋白去乙酰化酶小分子抑制剂的研究进展及展望
Hai-Tao Qin,Huan-Qiu Li,Feng Liu
Hai-Tao Qin
Since the first pan-HDAC inhibitor SAHA was approved by U.S. FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase activtiy has been implicated in a variety of human ...
Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part I: Curcumin [0.03%]
近年专利中有关姜黄素药物研发的新进展（2012-2016）第一部分：姜黄素
Rita Maria Concetta Di Martino,Barbara Luppi,Alessandra Bisi et al.
Rita Maria Concetta Di Martino et al.
curcumin is the main bioactive component contained in Curcuma Longa, largely employed in traditional medicine. Recently, beneficial properties, useful for prevention and treatment of several disorders, have been discovered for this compound...
Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents [0.03%]
新型白三烯生物合成抑制剂(2012-2016)作为抗炎剂的作用机制研究进展
Oliver Werz,Jana Gerstmeier,Ulrike Garscha
Oliver Werz
Leukotrienes (LTs) are lipid mediators produced from arachidonic acid with a broad variety of bioactivities in allergy and inflammation. The biosynthesis of LTs mainly involves 5-lipoxygenase (5-LO) and its 5-lipoxygenase-activating protein...